Core Insights - Nika Pharmaceuticals, Inc. is preparing for a significant year in 2026, with CEO Dimitar Savov discussing the company's progress and future expectations on The Street Reports podcast [1] Group 1: Company Developments - Nika Europe, a partner of Nika Pharmaceuticals, is finalizing the technical project for a new pharmaceutical factory, which is expected to begin construction soon and be completed by the end of Q1 2026 [2] - The production line equipment for the factory has already seen an investment of $387,088 and is currently in the final testing stages before installation [2] Group 2: Technical and Financial Aspects - The technical project for the factory has experienced delays, which are considered normal due to the complexities involved in building a state-of-the-art facility that meets GMP standards [3] - Specific costs associated with the factory include nearly $500,000 for the water for injections (WFI) system and over $1.1 million for the advanced HVAC system, indicating significant financial investment in infrastructure [3] Group 3: Company Profile - Nika Pharmaceuticals specializes in treatments for various diseases, including HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, and Diabetes, focusing on enhancing cell immunity [4] - The company's intellectual property portfolio includes six injectable drugs, two of which have successfully completed clinical trials, alongside four tablet drugs and eleven dietary supplements [4]